Banque Cantonale Vaudoise Has $3.16 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Banque Cantonale Vaudoise boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,835 shares of the medical equipment provider’s stock after acquiring an additional 3,682 shares during the period. Banque Cantonale Vaudoise’s holdings in Hologic were worth $3,163,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its stake in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after purchasing an additional 450,190 shares during the period. Black Creek Investment Management Inc. increased its holdings in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after buying an additional 124,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after buying an additional 87,176 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.3 %

HOLX stock opened at $78.57 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market capitalization of $18.25 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.48 and a beta of 0.98. The business has a fifty day moving average price of $80.56 and a 200 day moving average price of $78.30. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the previous year, the business posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of several research reports. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.